The purpose of this study was to investigate whether growth factors produced by activated human lung mast cells ( 
Introduction
β 2 -adrenoceptor (β 2 -AR) agonists represent the most commonly used drugs in the management of pulmonary diseases, including asthma [1] . These drugs provide relief from acute bronchoconstriction by promoting bronchodilation through direct activation of β 2 -AR on airway smooth muscle (ASM) and promoting its relaxation. Despite their clinical benefits, the use of β 2 -AR agonists in asthma has been associated with loss of β 2 -AR function, deleterious effects and/or worsening of the symptoms and asthma deaths [2] . Understanding the potential mechanisms that result in the loss of function and/or deleterious clinical effects in patients treated with β 2 -agonists could offer novel therapeutic alternatives.
Studies performed in different cell types have reported that some, but not all, growth factors can impair cell responsiveness to β 2 -agonists by phosphorylating β 2 -AR on several serine (ser 345/346 ) or tyrosine residues (Tyr 350/354/141 ), resulting in receptor uncoupling and internalization [3] [4] [5] [6] . In human lung mast cells (HLMCs), we showed that stem cell factor (SCF) can similarly uncouple β 2 -AR following receptor phosphorylation at similar Tyr 350 residues [7] . More recently, we observed that β 2 -AR responses were suppressed in both mast cells (suppression of FcεR1-induced activation) and ASM cells (inhibition of ASM contraction) following cell-cell contact via β 2 -AR phosphorylation, on Tyr 350 residues [8] . Whether mast cells also blunt β 2 -AR responses in ASM cells via the action of secreted different growth factors remains unknown.
The present study provides the first evidence that abnormal β2-AR phosphorylation/function can be induced experimentally by exposing healthy ASM cells to growth factors released from activated mast cells, a feature that was constitutively present in ASM cells from severe asthmatics. Abnormal tyrosine phosphorylation of β2-AR represents a novel mechanism that could explain the poor clinical efficacy of β 2 -AR therapy seen in severe asthma.
Materials and methods

Culture of human airway smooth muscle cells
Primary human ASM cells were obtained from consented healthy subjects and asthmatic patients isolated from endobronchial biopsies as described previously [9] . The demographics of subjects used in the study are shown in Fig. 3d .
Mast cell isolation, culture and stimulation
Isolation and stimulation of HLMC were performed as described previously [10] .
Flow cytometry
Flow cytometry assays were performed as described previously using the Becton Dickinson FACScan (Oxford, UK) [9] . The antibodies used were rabbit anti-human β2-AR (Tyr 141 ) antibody, rabbit anti-human β2-AR (Tyr 350 ) antibody (2 μg/ml; Santa Cruz Biotechnology, Santa Cruz, CA, USA), isotype-matched control (rabbit immunoglobulin (Ig)G; Imminostep, Salamanca, Spain) and secondary anti-rabbit fluorescein isothiocyanate (FITC; Cell Signaling Technology, Danvers, MA, USA).
Measurement of cyclic adenosine monophosphate (cAMP) production
ASM cells were stimulated with 10 µM albuterol for 10 min in the presence or absence of FcεR1-activated HLMC supernatants (1 : 4 dilution, added for different time-points or 10 min, as indicated) before cell extracts were used for the determination of intracellular cAMP concentration using the cAMP EIA kit from Amersham Biosciences (Little Chalfont, UK) (detection limit curve range > 25 fmol/well) following the manufacturer's protocol.
Collagen gel contraction assay
Spontaneous ASM cells contraction was examined in collagen gels, as described previously [8] .
Growth factor array
Supernatants were prepared from FcεR1-activated HLMCs, as described previously [10] , and were used to perform the growth factor array analysis which allows the simultaneous detection of 41 different human growth factors, following the manufacturer's protocol (Abcam, Cambridge, UK).
Human lung slice preparation
The bronchorelaxant responses using the six precision cut lung slices (PCLS) were performed as described previously [11] . The slices were incubated with transforming growth factor (TGF)-β or fibroblast growth factor (FGF)-2 at 100 ng/ml for 30 min before responses to isoproterenol were assessed on PCLS precontracted with 10 -4 M carbachol. The airway dilation data were expressed as percentage dilation of the maximum carbachol constricted airway luminal area with the baseline value prior to contraction considered as 100%, as described previously [11] .
Statistical analysis
All data are presented as mean ± standard error of the mean (s.e.m.). Statistical analysis was performed by twoor one-way analysis of variance (anova) with Bonferroni's correction for multiple comparisons. Differences were considered significant when P < 0·05. Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software, San Diego, CA, USA).
Results
FcεR1-activated HLMCs produced growth factors and attenuated the response to albuterol in human ASM cells
Representative protein array membrane showing growth factors) produced in the supernatants of resting and FcεR1-activated HLMCs [IgE (2·5 µg/ml)-anti-IgE (1 : 1000 dilution)] (Fig. 1a) . Densitometric analyses of the membrane arrays revealed that levels of FGF-2, epidermal growth factor (EGF), heparin-binding (HB)-EGF, hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, insulin-like growth factor binding protein IGF)-BP2, IGF-BP6, IGF-II, SCF, SCF-R, macrophage CSF (M-CSF), vascular endothelial growth factor (VEGF)-A, VEGF-D, VEGF-R3 and TGF-β1 were produced by FcεR1-activated HLMCs, although only four growth factors (GM-CSF, HGF, IGF-II and TGF-β1, P < 0·01) reached statistical significance. ASM cells first incubated with supernatants from FcεR1-activated HLMCs (compared to that of resting HLMCs) for different time-points (10-30 min) displayed a complete inhibition of cAMP accumulation measured in ASM cells treated with 10 µM albuterol for 10 min (n = 3 ASM cell lines, P < 0·01) (Fig. 1b) . The inhibitory effect of a 10-min incubation with FcεR1-activated HLMC supernatants on albuterol responses was almost completely prevented by incubating supernatants of FcεR1-activated HLMCs with 10 µg/ml neutralizing TGF-β1 antibody (Fig. 1c) .
TGF-β1 and FGF-2 induced β2-AR phosphorylation on key tyrosine residues and attenuated β2-AR responsiveness
Interestingly, only pretreatment of human ASM cells with either TGF-β1 or FGF-2 at 10 ng/ml for 10 min increased β2-AR phosphorylation significantly on both Tyr 141 (Fig.  2a) and Tyr 350 (Fig. 2b) , while VEGF or nerve growth factor (NGF) had no effect, despite having functional receptors in ASM cells [12] [13] [14] [15] . Figure 2c shows that TGF-β1 and FGF-2 also reduced cAMP responses to albuterol by more than 85 and 72%, respectively (n = 3). Figure 2d shows that isoproterenol-evoked bronchodilatation assessed using human PCLS was inhibited by TGF-β1 or FGF-2 (30 min, 100 ng/ml), with a reduction of the maximum % bronchodilation from 57·44 ± 4·11 to 34·29 ± 5·37 and 32·4 ± 2·39 (n = 6 slices, P < 0·05), respectively. Both growth factors had no effect on isoproterenol EC 50 value (logEC 50 = -6·27 ± 0·2099).
ASM cells from severe asthmatics display an increased basal β2-AR phosphorylation at tyrosine residues and an impaired relaxant response to albuterol
Our flow cytometry data show that ASM cells derived from severe asthmatics, but not from non-severe asthmatics, displayed a constitutive increased phosphorylation of β2-AR at both Tyr 141 (Fig. 3a , geometric mean fluorescence intensity (GMFI) = 31·13 ± 2·54, P = 0·0045, n = 7) and Tyr 350 (Fig. 3b , GMFI = 31·22 ± 2·40, P = 0·0224, n = 7) when compared to levels seen in healthy subjects (GMFI = 10·03 ± 3·05 and 13·76 ± 4·23, n = 7). Gel contraction assays also revealed that albuterol failed to abrogate the spontaneous contraction of severe asthmatic ASM cells while reducing by more than 47% the response seen in healthy ASM cells ( Fig. 3c , P < 0·05, n = 3). Figure 3d shows the demographics of the subjects used in the studies. Data are shown as means ± s.e.m.
Discussion
The possibility that cell-cell interactions between mast cells and ASM cells may play a role in the pathogenesis of asthma is supported by multiple in-vitro reports showing the ability of mast cell mediators to induce various pro-asthmatic responses in ASM cells/tissues [2] . We found that β2-AR dysfunction in human ASM cells could be induced experimentally by exposing human ASM cells with supernatants from activated HLMCs, which produced a number of growth factors, although only four (GM-CSF, HGF, IGF-II and TGF-β1) reached statistical significance. The observation that HLMC effect was largely prevented by the presence of neutralizing TGF-β1 antibody, or mimicked by the pretreatment of ASM cells with exogenous TGF-β1 (or FGF-2), identified TGF-β1 as a novel modulator of β2-AR function. We believe that the central mechanism by which TGF-β1 impaired β2-AR function in ASM cells results from its capacity to phosphorylate the receptor rapidly at two key tyrosine residues, Tyr 141 and Tyr 350 , which was seen within 10 min. This hypothesis is supported by our recent finding that β2-AR phosphorylation at Tyr 350 in HLMCs was essential in driving the loss of β2-AR responses when exposed to another mast cell mediator SCF [7] or following adhesion of HLMCs to ASM cells [8] . Whether TGF-β1 interferes with β2-AR responses by acting at a level downstream to β2-AR remains a possibility, although a previous study also performed in human ASM cells showed that TGF-β1 inhibited isoproterenol-induced cAMP production by decreasing [4, 6, 18] . It is noteworthy to mention that, irrespective of the type of growth factors, β 2 -AR phosphorylation on tyrosine residues is a key trigger of receptor dysfunction [6, 18] . Our PCLS model, used widely to study ASM contractile/relaxant responses [19] , confirmed that either TGF-β1 and FGF-2 (although used at much higher concentrations, due possibly to tissue complexity of the PCLS) reduced β2-AR-evoked bronchorelaxant responses dramatically. Although a different agonist (isoproterenol) was used in PCLS, both albuterol and isoproterenol were shown to have a similar bronchodilatory profile in patients [20] . Our study shows that in addition to tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-13 or IL-5, both TGF-β1 or FGF-2 can also drive β 2 -AR dysfunction in human ASM cells (reviewed in [21] ). We also made the novel finding that ASM cells from severe asthmatics displayed a constitutive tyrosine phosphorylation of β 2 -ARs and blunted response to albuterol in the collagen gel assays. Because ASM cells from severe asthmatics also have a reduced sensitivity to corticosteroids [22] [23] [24] , our study further supports the existence of the factors in severe asthma that blunt the response to the two main anti-asthma drugs. Our study shows that β 2 -AR dysfunction in ASM in asthma could result from the transient (induced by growth factors) or permanent (unknown mechanisms) phosphorylation of the receptor at both Tyr 141 and Tyr 350 residues. We propose that targeting the mechanisms leading to abnormal β 2 -AR phosphorylation have the potential to enhance β2-agonist activity in patients with asthma, and perhaps reduce the unwanted adverse effects sometimes evident with their chronic use [21] .
